Table 4 Prevalence of side effects associated with targeted and osteo-oncologic therapy for breast cancer 1, 2.

Targeted therapy (trastuzumab [Herceptin®], lapatinib [Tyverb®], pertuzumab [Perjeta®], trastuzumab emtansin [T-DM1, Kadcyla®], bevacizumab [Avastin®])
Common:
16–67 %	Gastrointestinal complaints
27 %	Muscle and joint pain
23–24 %	Skin rash/erythema
21 %	Headache
12–15 %	Fever/chills
10–14 %	Flu-like symptoms
11 %	Dizziness
> 10 %	Blood count changes (anemia, thrombopenia, leukopenia)
1–10 %	Fluctuations in blood pressure
> 10 %	Cardiac arrhythmia
1–10 %	Cardiac insufficiency
Rare:
< 0.1 %	Pericardial effusion/pleural effusion
Osteo-oncologic treatment (zoledronic acid [Zometa®, Aclasta®], denosumab [Xgeva®, Prolia®], ibandronate [Bondronat®], alendronate [Fosamax®], risedronate [Actonel®])
Common:
> 10 %	Hypocalcemia and hypophosphatemia
> 10 %	Flu-like symptoms
9 %	Headache
3–7 %	Fever/chills
3 %	Bone and joint pain
1–10 %	Gastrointestinal complaints
1–10 %	Renal function disorders
1–10 %	Anemia
1–10 %	Skin rash
Rare:
< 0.1 %	Jaw osteonecrosis
< 0.1 %	Cardiac arrhythmia